These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38316746)

  • 1. Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM).
    Mill CP; Fiskus WC; DiNardo CD; Reville P; Davis JA; Birdwell CE; Das K; Hou H; Takahashi K; Flores L; Ruan X; Su X; Loghavi S; Khoury JD; Bhalla KN
    Blood Cancer J; 2024 Feb; 14(1):25. PubMed ID: 38316746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.
    Mill CP; Fiskus W; DiNardo CD; Birdwell C; Davis JA; Kadia TM; Takahashi K; Short N; Daver N; Ohanian M; Borthakur G; Kornblau SM; Green MR; Qi Y; Su X; Khoury JD; Bhalla KN
    Blood; 2022 Feb; 139(6):907-921. PubMed ID: 34601571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients.
    Sakurai M; Kunimoto H; Watanabe N; Fukuchi Y; Yuasa S; Yamazaki S; Nishimura T; Sadahira K; Fukuda K; Okano H; Nakauchi H; Morita Y; Matsumura I; Kudo K; Ito E; Ebihara Y; Tsuji K; Harada Y; Harada H; Okamoto S; Nakajima H
    Leukemia; 2014 Dec; 28(12):2344-54. PubMed ID: 24732596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A new form of familial platelet disorder caused by germline mutations in RUNX1 in a pedigree].
    Guan J; Wang LL; Wang CY; Zhu XM; Shuai HZ; Yi X; Zou L; Yu D; Cheng H
    Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):393-400. PubMed ID: 37032134
    [No Abstract]   [Full Text] [Related]  

  • 5. [Familial platelet disorder with predisposition to myeloid leukemia (FPD/AML): a case report and literature review].
    Zhang RR; Chen XJ; Ren YY; Yang WY; Zhu XF
    Zhonghua Xue Ye Xue Za Zhi; 2021 Apr; 42(4):308-312. PubMed ID: 33979975
    [No Abstract]   [Full Text] [Related]  

  • 6. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis.
    Michaud J; Wu F; Osato M; Cottles GM; Yanagida M; Asou N; Shigesada K; Ito Y; Benson KF; Raskind WH; Rossier C; Antonarakis SE; Israels S; McNicol A; Weiss H; Horwitz M; Scott HS
    Blood; 2002 Feb; 99(4):1364-72. PubMed ID: 11830488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted correction of RUNX1 mutation in FPD patient-specific induced pluripotent stem cells rescues megakaryopoietic defects.
    Connelly JP; Kwon EM; Gao Y; Trivedi NS; Elkahloun AG; Horwitz MS; Cheng L; Liu PP
    Blood; 2014 Sep; 124(12):1926-30. PubMed ID: 25114263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder.
    Preudhomme C; Renneville A; Bourdon V; Philippe N; Roche-Lestienne C; Boissel N; Dhedin N; André JM; Cornillet-Lefebvre P; Baruchel A; Mozziconacci MJ; Sobol H
    Blood; 2009 May; 113(22):5583-7. PubMed ID: 19357396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysmegakaryopoiesis of FPD/AML pedigrees with constitutional RUNX1 mutations is linked to myosin II deregulated expression.
    Bluteau D; Glembotsky AC; Raimbault A; Balayn N; Gilles L; Rameau P; Nurden P; Alessi MC; Debili N; Vainchenker W; Heller PG; Favier R; Raslova H
    Blood; 2012 Sep; 120(13):2708-18. PubMed ID: 22898599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CBL mutation in chronic myelomonocytic leukemia secondary to familial platelet disorder with propensity to develop acute myeloid leukemia (FPD/AML).
    Shiba N; Hasegawa D; Park MJ; Murata C; Sato-Otsubo A; Ogawa C; Manabe A; Arakawa H; Ogawa S; Hayashi Y
    Blood; 2012 Mar; 119(11):2612-4. PubMed ID: 22138511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre-leukaemic clone resulting in T2-ALL and AML-M0.
    Manchev VT; Bouzid H; Antony-Debré I; Leite B; Meurice G; Droin N; Prebet T; Costello RT; Vainchenker W; Plo I; Diop M; Macintyre E; Asnafi V; Favier R; Baccini V; Raslova H
    J Cell Mol Med; 2017 Jun; 21(6):1237-1242. PubMed ID: 27997762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted gene correction of RUNX1 in induced pluripotent stem cells derived from familial platelet disorder with propensity to myeloid malignancy restores normal megakaryopoiesis.
    Iizuka H; Kagoya Y; Kataoka K; Yoshimi A; Miyauchi M; Taoka K; Kumano K; Yamamoto T; Hotta A; Arai S; Kurokawa M
    Exp Hematol; 2015 Oct; 43(10):849-57. PubMed ID: 26021490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy.
    Owen CJ; Toze CL; Koochin A; Forrest DL; Smith CA; Stevens JM; Jackson SC; Poon MC; Sinclair GD; Leber B; Johnson PR; Macheta A; Yin JA; Barnett MJ; Lister TA; Fitzgibbon J
    Blood; 2008 Dec; 112(12):4639-45. PubMed ID: 18723428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low Mpl receptor expression in a pedigree with familial platelet disorder with predisposition to acute myelogenous leukemia and a novel AML1 mutation.
    Heller PG; Glembotsky AC; Gandhi MJ; Cummings CL; Pirola CJ; Marta RF; Kornblihtt LI; Drachman JG; Molinas FC
    Blood; 2005 Jun; 105(12):4664-70. PubMed ID: 15741216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms underlying platelet function defect in a pedigree with familial platelet disorder with a predisposition to acute myelogenous leukemia: potential role for candidate RUNX1 targets.
    Glembotsky AC; Bluteau D; Espasandin YR; Goette NP; Marta RF; Marin Oyarzun CP; Korin L; Lev PR; Laguens RP; Molinas FC; Raslova H; Heller PG
    J Thromb Haemost; 2014 May; 12(5):761-72. PubMed ID: 24606315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Familial leukemia due to germline RUNX1 mutations: lessons learned from two decades of research and unsolved problems].
    Osato M; Nambu A
    Rinsho Ketsueki; 2020; 61(6):687-696. PubMed ID: 32624544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent CDC25C mutations drive malignant transformation in FPD/AML.
    Yoshimi A; Toya T; Kawazu M; Ueno T; Tsukamoto A; Iizuka H; Nakagawa M; Nannya Y; Arai S; Harada H; Usuki K; Hayashi Y; Ito E; Kirito K; Nakajima H; Ichikawa M; Mano H; Kurokawa M
    Nat Commun; 2014 Aug; 5():4770. PubMed ID: 25159113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid neoplasms with germ line RUNX1 mutation.
    Hayashi Y; Harada Y; Huang G; Harada H
    Int J Hematol; 2017 Aug; 106(2):183-188. PubMed ID: 28534116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of eriocalyxin B and homoharringtonine exerts synergistic anti-tumor effects against t(8;21) AML.
    Lei YC; Chen XJ; Dai YT; Dai B; Wang JY; Li MH; Liu P; Liu H; Wang KK; Jiang L; Chen B
    Acta Pharmacol Sin; 2024 Mar; 45(3):633-645. PubMed ID: 38017299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders.
    Latger-Cannard V; Philippe C; Bouquet A; Baccini V; Alessi MC; Ankri A; Bauters A; Bayart S; Cornillet-Lefebvre P; Daliphard S; Mozziconacci MJ; Renneville A; Ballerini P; Leverger G; Sobol H; Jonveaux P; Preudhomme C; Nurden P; Lecompte T; Favier R
    Orphanet J Rare Dis; 2016 Apr; 11():49. PubMed ID: 27112265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.